Manufacturers Increasing Prices in Lockstep to Raise Prices Across New Drug Category Vaccines against respiratory syncytial virus (RSV) approved by the U.S. Food and Drug Administration (FDA) are so new they aren’t even widely available to patients — but that hasn’t stopped their Big Pharma manufacturers from scheming to increase their price to boost profits. […]
Lawmakers Should Focus on Bipartisan Solutions to Hold Big Pharma Accountable, Reject Legislation that Would Undermine True Innovation and Competition Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Friday in response to the reintroduction of The Patent Eligibility Restoration Act in the U.S. Senate. “Big Pharma’s abuse of the patent system to block […]
Senate Panel Passes Bills to Increase Competition and Increase List Price Transparency Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement today on the advancement of several bipartisan solutions that will help hold Big Pharma accountable by the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP). “CSRxP commends the leadership and members of the HELP […]
U.S. Senate HELP Committee Should Advance Legislation to Boost Competition and Increase List Price Transparency Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement today ahead of an executive session in the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP), where lawmakers are expected to vote on several bipartisan solutions that will help hold Big Pharma accountable. […]
Nearly 500 Percent Price Increase on Vaccine Developed with Taxpayer Investment Highlights Urgency to Hold Big Pharma Accountable Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Thursday in response to reports that brand name drug maker Moderna plans to continue moving ahead with a plan to charge between $110 and $130 for […]
Bipartisan Transparency Legislation Will Help Hold Big Pharma Accountable for Egregious Pricing Practices Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement today applauding the reintroduction of The Fair Accountability and Innovative Research (FAIR) Drug Pricing Act in the U.S. Senate. “We applaud Senators Baldwin and Braun for reintroducing this market-based solution that will help hold Big Pharma accountable and […]
Senate HELP Committee Hearing with Moderna CEO Offers Prime Opportunity to Push Back on Brand Name Drug Company Profiteering Ahead of Shift to Commercial Distribution Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement ahead of a Wednesday hearing in the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP) with […]
More Big Pharma Companies Should Also Lower Their Insulin Prices, But Policymakers Must Address Root Cause of High Drug Prices To Secure Lasting Relief Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Wednesday in response to an announcement from Eli Lilly and Company (Lilly) that the brand name drug maker plans to limit list […]
Senate Judiciary Committee Advances Critical Legislation to Crack Down on Brand Name Drug Companies’ Anti-Competitive Tactics that Extend Monopolies and Keep Prices High Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Thursday following the passage of the Affordable Prescriptions for Patients Act of 2023 in the U.S. Senate Committee on the Judiciary. […]
Policies Must Address Big Pharma’s Egregious Practices That Cause High Drug Prices Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released the following statement Tuesday on President Biden’s remarks on prescription drug prices during the State of the Union address. “CSRxP applauds the positive progress made by President Biden and lawmakers in the last […]